BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28299757)

  • 1. Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages.
    Lee MS; Dees EC; Wang AZ
    Oncology (Williston Park); 2017 Mar; 31(3):198-208. PubMed ID: 28299757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine: An effective tool in cancer therapy.
    Aftab S; Shah A; Nadhman A; Kurbanoglu S; Aysıl Ozkan S; Dionysiou DD; Shukla SS; Aminabhavi TM
    Int J Pharm; 2018 Apr; 540(1-2):132-149. PubMed ID: 29427746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle-assisted combination therapies for effective cancer treatment.
    Hu CM; Aryal S; Zhang L
    Ther Deliv; 2010 Aug; 1(2):323-34. PubMed ID: 22816135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoscale drug delivery for targeted chemotherapy.
    Xin Y; Huang Q; Tang JQ; Hou XY; Zhang P; Zhang LZ; Jiang G
    Cancer Lett; 2016 Aug; 379(1):24-31. PubMed ID: 27235607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nano drug-delivery systems in cancer therapy: gains, pitfalls and considerations in DMPK and PD.
    Elbayoumi TA
    Ther Deliv; 2010 Aug; 1(2):215-9. PubMed ID: 22816128
    [No Abstract]   [Full Text] [Related]  

  • 7. Polymeric nano-micelles: versatile platform for targeted delivery in cancer.
    Mohamed S; Parayath NN; Taurin S; Greish K
    Ther Deliv; 2014 Oct; 5(10):1101-21. PubMed ID: 25418269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomes and inorganic nanoparticles for drug delivery and cancer imaging.
    Heneweer C; Gendy SE; Peñate-Medina O
    Ther Deliv; 2012 May; 3(5):645-56. PubMed ID: 22834408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telodendrimer-based nanocarriers for the treatment of ovarian cancer.
    Xiao K; Suby N; Li Y; Lam KS
    Ther Deliv; 2013 Oct; 4(10):1279-92. PubMed ID: 24116912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects.
    Wang Y; Wei X; Zhang C; Zhang F; Liang W
    Ther Deliv; 2010 Aug; 1(2):273-87. PubMed ID: 22816133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.
    La-Beck NM; Islam MR; Markiewski MM
    Front Immunol; 2020; 11():603039. PubMed ID: 33488603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocarriers for cancer-targeted drug delivery.
    Kumari P; Ghosh B; Biswas S
    J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug delivery systems using polymer nanoassemblies for cancer treatment.
    Bae Y
    Ther Deliv; 2010 Sep; 1(3):361-3. PubMed ID: 22816139
    [No Abstract]   [Full Text] [Related]  

  • 14. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
    Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
    Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Size matters: gold nanoparticles in targeted cancer drug delivery.
    Dreaden EC; Austin LA; Mackey MA; El-Sayed MA
    Ther Deliv; 2012 Apr; 3(4):457-78. PubMed ID: 22834077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting liposomes toward novel pediatric anticancer therapeutics.
    Federman N; Denny CT
    Pediatr Res; 2010 May; 67(5):514-9. PubMed ID: 20118828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.
    Malam Y; Loizidou M; Seifalian AM
    Trends Pharmacol Sci; 2009 Nov; 30(11):592-9. PubMed ID: 19837467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetic model for quantifying the effect of vascular permeability on the choice of drug carrier: a framework for personalized nanomedicine.
    Kirtane AR; Siegel RA; Panyam J
    J Pharm Sci; 2015 Mar; 104(3):1174-86. PubMed ID: 25583443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors.
    Stylianopoulos T
    Ther Deliv; 2013 Apr; 4(4):421-3. PubMed ID: 23557281
    [No Abstract]   [Full Text] [Related]  

  • 20. Extracellular stability of nanoparticulate drug carriers.
    Liu KC; Yeo Y
    Arch Pharm Res; 2014 Jan; 37(1):16-23. PubMed ID: 24214175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.